AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

This study tests a new experimental drug called AVA6103 in patients with certain advanced solid tumors that express a protein called FAP (fibroblast activation protein) on their surface. The cancers being studied include cervical/vulvar cancer, small cell lung cancer, stomach/esophageal junction cancer, and pancreatic cancer that have progressed after standard treatments. **You may be eligible if...** - You are 18 or older with a confirmed advanced or metastatic form of one of the qualifying cancers - Your cancer has already received all available standard treatments, or you cannot receive or do not want those treatments - You are in good physical condition (ECOG 0–1) - Your organ function (blood counts, liver, kidneys) is adequate **You may NOT be eligible if...** - You have active or untreated brain metastases - You have another active cancer (other than minor skin cancers or early prostate cancer) - You have active HIV (unless well-controlled), active hepatitis B or C, or a recent severe infection - You have had major surgery within 21 days before the study - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.